Skip to main content
MPLT
NASDAQ Life Sciences

ML-004 Phase 2 IRIS Trial Misses Primary Endpoint but Shows Strong Efficacy in ASD Irritability

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$25.92
Mkt Cap
$1.228B
52W Low
$12.24
52W High
$33.28
52W Position info
112% above low
Off High info
22% below high
Rel. Volume info
4.6× avg
Market data snapshot near publication time

MPLT has more than doubled off its 52-week low of $12.24 on elevated volume (4.6× avg).

Summary

MapLight Therapeutics' ML-004 Phase 2 IRIS trial missed its primary endpoint for social communication in ASD but showed strong, differentiated efficacy in reducing irritability in adolescents, paving the way for a new development path.


Key Events · Product Development and Regulatory · MPLT

  • ML-004 Phase 2 IRIS Trial Results

    The study did not meet its primary endpoint for social communication deficits in autism spectrum disorder (ASD).

  • Strong Efficacy in Irritability

    ML-004 showed clinically meaningful improvement in irritability in adolescents with moderate-to-severe baseline irritability, with effect sizes of 1.33 (caregiver-reported) and 1.08 (clinician-rated).

  • Favorable Safety Profile

    The drug was well-tolerated with no severe adverse events, no extrapyramidal symptoms, and lower weight gain compared to placebo, offering differentiation from current treatments.

  • New Development Path

    MapLight plans to engage with the FDA for End-of-Phase 2 discussions to pursue ML-004 for irritability in ASD, an area of high unmet medical need.


Analysis · MPLT · Life Sciences

MapLight Therapeutics announced mixed Phase 2 results for ML-004 in autism spectrum disorder. While the study did not meet its primary endpoint for social communication deficits, it demonstrated clinically meaningful improvements in irritability in adolescents with moderate-to-severe baseline irritability. The drug also showed a favorable safety profile, notably with no extrapyramidal events and lower weight gain compared to placebo, offering a potential differentiation from existing antipsychotics. The company plans to engage with the FDA to pursue development for this indication, which has a high unmet medical need.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MPLT was trading at $25.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MPLT - Latest Insights

MPLT
Nov 16, 2026, 7:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $7.03 info
Change: -$0.340 (-5%) info
Market Cap: $383.472M info
MPLT
Nov 16, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $7.03 info
Change: -$0.340 (-5%) info
Market Cap: $383.472M info
MPLT
Nov 16, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $7.03 info
Change: -$0.220 (-3%) info
Market Cap: $383.472M info
MPLT
Aug 18, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $7.03 info
Change: -$4.56 (-39%) info
Market Cap: $383.472M info
MPLT
Aug 18, 2026, 6:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $7.03 info
Change: -$4.56 (-39%) info
Market Cap: $383.472M info